Stephen Michael Moore Sells 2,068 Shares of Personalis (NASDAQ:PSNL) Stock

Key Points

• Personalis SVP Stephen Michael Moore sold 2,068 shares at an average price of $16.22, generating $33,542.96. The sale covered tax withholding obligations tied to vested equity awards, reducing his holdings by 2.24% to 90,257 shares.
• PSNL recently traded at $16.36, near its 52-week high of $18.89, with a $1.71 billion market capitalization. The company reported quarterly revenue of $22.36 million but missed earnings expectations, posting an EPS loss of $0.30.
• Analyst sentiment is mixed, with four Buy, five Hold, and one Sell rating; the consensus rating is Hold with a $14.54 price target. Institutional investors own approximately 61.91% of the company.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) SVP Stephen Moore sold 2,068 shares of the business's stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $33,542.96. Following the completion of the transaction, the senior vice president directly owned 90,257 shares of the company's stock, valued at approximately $1,463,968.54. This represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Personalis Stock Performance

NASDAQ PSNL traded up $0.12 during mid-day trading on Tuesday, reaching $16.36. 1,369,078 shares of the stock were exchanged, compared to its average volume of 2,690,633. Personalis, Inc. has a 1-year low of $4.95 and a 1-year high of $18.89. The business's fifty day simple moving average is $15.06 and its 200 day simple moving average is $10.89. The stock has a market capitalization of $1.71 billion, a PE ratio of -15.01 and a beta of 2.31.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The business had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. On average, analysts anticipate that Personalis, Inc. will post -1.07 EPS for the current year.

Institutional Trading of Personalis

A number of institutional investors have recently modified their holdings of the company. Merck & Co. Inc. acquired a new stake in shares of Personalis in the second quarter worth $188,202,236. Dimensional Fund Advisors LP boosted its position in Personalis by 8.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company's stock worth $6,791,000 after purchasing an additional 83,074 shares during the period. Sei Investments Co. boosted its position in Personalis by 148.3% during the 1st quarter. Sei Investments Co. now owns 139,046 shares of the company's stock worth $886,000 after purchasing an additional 83,040 shares during the period. Deutsche Bank AG acquired a new stake in shares of Personalis in the second quarter valued at about $887,000. Finally, Tidal Investments LLC acquired a new stake in Personalis in the second quarter valued at approximately $1,146,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Analysts Set New Price Targets

PSNL has been the topic of several recent analyst reports. BTIG Research increased their target price on Personalis from $11.00 to $16.25 and gave the stock a "buy" rating in a research report on Monday, July 20th. Zacks Research upgraded Personalis from a "strong sell" rating to a "hold" rating in a report on Monday, September 7th. Needham & Company LLC downgraded shares of Personalis from a "buy" rating to a "hold" rating in a research note on Monday, July 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Personalis in a report on Friday, July 17th. Finally, Lake Street Capital cut shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 target price on the stock. in a research report on Monday, July 20th. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $14.54.

Personalis Company Profile

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis' technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.